Mevalonate Pathway

The mevalonate pathway, also called the HMG-CoA reductase pathway, is a primary biosynthetic route in cannabis that produces isoprenoid precursors essential for cannabinoid and terpene synthesis. This metabolic sequence converts acetyl-CoA into isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), building blocks for all C5-unit terpenes and the prenyl side chain of cannabinoids. Genetic variation in pathway enzymes—including HMG-CoA synthase, HMG-CoA reductase, and mevalonate kinase—influences secondary metabolite accumulation across cultivars. Breeders studying this pathway examine how enzyme expression correlates with terpene diversity, cannabinoid yield, and plant vigor. Understanding mevalonate flux helps explain phenotypic differences in aroma intensity and chemotype distribution across cannabis genetics.

Breeders working with terpene-rich or high-cannabinoid lines investigate mevalonate pathway expression as a lever for enhancing volatile and non-volatile isoprenoid production. Crosses targeting specific terpene profiles or cannabinoid abundance often track pathway enzyme activity as a proxy for metabolic capacity.